These results identify CRID3 as a novel inhibitor of the NLRP3 and AIM2 inflammasomes and provide an insight into the mechanism of action of this small molecule.
http://plosone.org/article/info:doi/10.1371/journal.pone.0029539#article1.front1.article-meta1.abstract1.sec3.p1

In this article we reported that a compound provided by Amgen, termed CRID3, could inhibit both the NLRP3 inflammasome and the AIM2 inflammasome at μM potency. We have subsequently found that the CRID3 compound is actually an inhibitor of NLRP3 inflammasome activation with an IC50 of approx. 10nM. Importantly, it does not inhibit AIM2 inflammasome activation. The differences observed with the findings in our article were discovered when the CRID3 obtained from Amgen used in this article was analysed by LC-MS and NMR and found to be a different structure, namely 1-(5-carboxy-2-{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic
acid as decribed by Harter, M. et al. U.S Patent 7,498,460, 2009. The error happened owing to incorrect labelling of the vial containing what we thought was CRID3. The actual CRID3 which we had synthesised ourselves, is therefore much more specific and potent.